Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Corline Biomedical AB (CLBIO.ST)
Uppsala, UP, SE
Corline Biomedical AB is a company dedicated to the creation, production, and distribution of heparin-based solutions. These solutions are specifically engineered to enhance outcomes in kidney transplantation, cellular therapies, and regenerative medicine. At the heart of their product line is the proprietary Corline Heparin Conjugate (CHC) technology, a unique heparin conjugate that can function as a standalone pharmaceutical compound. The company's diverse portfolio includes Renaparin, aimed at treating end-stage renal failure; Cytoparin, a cell therapy designed for patients with type 1 diabetes; the CHC compound itself for addressing soft tissue injuries; and a variety of medical devices, such as CHS, a coronary stent. Established in 1991, Corline Biomedical AB operates from its headquarters in Uppsala, Sweden.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +3.11% | +4.58% | +10.61% | +19.67% | -7.83% | +5.49% | +82.50% | +15.87% | +67.43% | +131.01% | +79.93% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%-21.7% Q1'26: +108.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+44.3% ★ Q1'26: +24.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-225.5% Q1'26: -138.8% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-185.7% Q1'26: -56.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-19.4% Q1'26: -14.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+13.4% Q1'26: +4.6% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.04M
est: 1.00M (+3.7%)
|
947.0K
est: 1.00M (-5.3%)
|
638.0K
est: 1.00M (-36.2%)
|
1.56M
est: 2.00M (-21.9%)
|
1.06M
est: 4.00M (-73.4%)
|
3.70M
est: 1.00M (+269.6%)
|
7.06M
est: 5.00M (+41.2%)
|
23.55M
est: 21.00M (+12.1%)
|
25.03M
est: 25.00M (+0.1%)
|
9.78M
est: 13.95M (-29.9%)
|
7.65M
est: 13.20M (-42.0%)
|
41.80M
41.80M – 41.80M
+216.7% YoY
|
94.70M
94.70M – 94.70M
+126.6% YoY
|
143.20M
143.20M – 143.20M
+51.2% YoY
|
| EBITDA |
-5.65M
est: -588.0K (-860.5%)
|
-5.22M
est: -588.0K (-787.4%)
|
-7.81M
est: -588.0K (-1,227.7%)
|
-6.79M
est: -1.18M (-477.5%)
|
-9.53M
est: -2.35M (-305.2%)
|
-7.27M
est: -588.0K (-1,136.6%)
|
-6.88M
est: -2.94M (-133.9%)
|
2.39M
est: -12.35M (+119.3%)
|
-1.69M
est: -14.70M (+88.5%)
|
-23.07M
est: -8.20M (-181.2%)
|
-14.12M
est: -7.76M (-82.0%)
|
-24.58M
-24.58M – -24.58M
-216.7% YoY
|
-55.68M
-55.68M – -55.68M
-126.6% YoY
|
-84.20M
-84.20M – -84.20M
-51.2% YoY
|
| EBIT |
-5.68M
est: -590.1K (-861.6%)
|
-5.22M
est: -590.1K (-784.5%)
|
-7.81M
est: -590.1K (-1,223.1%)
|
-6.79M
est: -1.18M (-475.5%)
|
-9.54M
est: -2.36M (-304.1%)
|
-7.29M
est: -590.1K (-1,134.5%)
|
-6.91M
est: -2.95M (-134.1%)
|
2.33M
est: -12.39M (+118.8%)
|
-1.78M
est: -14.75M (+87.9%)
|
-23.16M
est: -8.23M (-181.4%)
|
-14.21M
est: -7.79M (-82.4%)
|
-24.67M
-24.67M – -24.67M
-216.7% YoY
|
-55.89M
-55.89M – -55.89M
-126.6% YoY
|
-84.51M
-84.51M – -84.51M
-51.2% YoY
|
| Net Income |
-5.85M
est: -30.64M (+80.9%)
|
-5.25M
est: -17.39M (+69.8%)
|
-7.81M
est: -22.69M (+65.6%)
|
-6.79M
est: -9.12M (+25.5%)
|
-9.54M
est: -11.03M (+13.5%)
|
-7.29M
est: -28.42M (+74.4%)
|
-6.92M
est: -23.99M (+71.2%)
|
2.33M
est: -8.29M (+128.1%)
|
-1.81M
est: -1.96M (+7.8%)
|
-23.19M
est: -1.24M (-1,775.5%)
|
-14.71M
est: 4.95M (-397.4%)
|
17.31M
17.31M – 17.31M
+250.0% YoY
|
29.68M
29.68M – 29.68M
+71.4% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
2.54M
est: 1.52M (+67.3%)
|
6.92M
est: 1.52M (+355.9%)
|
11.94M
est: 1.52M (+687.5%)
|
5.45M
est: 3.03M (+79.6%)
|
16.69M
est: 6.07M (+175.1%)
|
6.22M
est: 1.52M (+310.0%)
|
15.95M
est: 7.58M (+110.3%)
|
20.89M
est: 31.85M (-34.4%)
|
—
est: 37.92M (-100.0%)
|
26.93M
est: 16.46M (+63.6%)
|
—
est: 15.58M (-100.0%)
|
49.33M
49.33M – 49.33M
+216.7% YoY
|
111.76M
111.76M – 111.76M
+126.6% YoY
|
169.00M
169.00M – 169.00M
+51.2% YoY
|
| EPS |
-0.68
est: -1.40 (+51.6%)
|
-0.43
est: -0.80 (+46.1%)
|
-0.59
est: -1.04 (+43.3%)
|
-0.44
est: -0.42 (-5.2%)
|
-0.57
est: -0.51 (-12.7%)
|
-0.42
est: -1.30 (+67.8%)
|
-0.34
est: -1.10 (+69.1%)
|
0.11
est: -0.38 (+128.9%)
|
-0.08
est: -0.09 (+6.4%)
|
-1.06
est: -0.05 (-2,020.0%)
|
-0.59
est: 0.20 (-395.0%)
|
0.70
0.70 – 0.70
+250.0% YoY
|
1.20
1.20 – 1.20
+71.4% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Asa Holm | Chief Operating Officer | — | female |
| Henrik Nittmar | Chief Executive Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CLBIO.ST
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
